In this report,in the last several years, Global market of Transdermal Drug Delivery System developed rapidly, with an average sales growth rate of 13.4%. In 2016, global revenue of Transdermal Drug Delivery System was nearly 8000 million USD; the actual production is about 13300 million units. The classification of Transdermal Drug Delivery System includes Fentanyl, Nitroglycerin, Estradiol, Nicotine and Other, and the revenue proportion of Fentanyl in 2016 was about 31%. The transdermal drug delivery systems market is segmented on the basis of type of delivery system, application And regions.
Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. The unprecedented global shift in the adoption of unhealthy lifestyles is to be responsible for the high prevalence of chronic diseases, such as cancer and diabetes, which is expected to drive the clinical urgency to incorporate transdermal drug delivery systems in the future treatments. Moreover, the rising geriatric population base, which is highly susceptible to developing the aforementioned chronic diseases are expected to propel the demand for highly efficacious pharmacological drugs.
Transdermal Drug Delivery System can be used for OTC and Rx. The most proportion of Transdermal Drug Delivery System is OTC, and the sales proportion was about 83% in 2016.
Market competition is intense. Hisamitsu, Mylan, Johnson & Johnson, Actavis, etc. are the leaders of the industry.
North America was the largest sales place, with revenue market share nearly 41% in 2016. Following North America, Europe is the second largest sales place. China and Japan are also important sales regions for Transdermal Drug Delivery System.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Transdermal Drug Delivery System in these regions, from 2014 to 2026 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Transdermal Drug Delivery System market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacture.
Key Market Players Including
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
UCB
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum Company
Laboratoires Genevrier
Other
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Transdermal Drug Delivery System for each application, including
OTC
Rx
On the basis of end users, the transdermal drug delivery systems market has been segmented including:
Home Care Settings
Hospitals And Clinics
If you have any special requirements, please let us know and we will offer you the report as you want.